Sanofi (SNY) Downgraded by Zacks Investment Research
Zacks Investment Research lowered shares of Sanofi (NYSE:SNY) from a buy rating to a hold rating in a report issued on Tuesday morning.
According to Zacks, “Sanofi’s focus on streamlining operations and pursuing business development deals is encouraging. It has several new products in its portfolio and candidates in its pipeline that can boost long-term growth. In fact, Sanofi’s product launches are now delivering revenues greater than the loss of exclusivity impact. Particularly, we are optimistic about Dupixent’s sales prospects, which could prove to be an important growth driver. The performance of the Vaccines and Consumer Healthcare units has also improved lately. However, headwinds include a bleak outlook for the Diabetes franchise, generic competition for many drugs and slower-than-expected uptake of core products like Praluent. Shares of Sanofi have outperformed the industry in the past six months. Estimates have gone down slightly ahead of Q4 earnings release. Sanofi has a mixed record of earnings surprises in recent quarters.”
Other equities analysts have also issued reports about the company. ValuEngine raised Sanofi from a sell rating to a hold rating in a report on Wednesday, October 17th. Morgan Stanley assumed coverage on Sanofi in a report on Friday, December 14th. They issued an equal weight rating for the company. Guggenheim assumed coverage on Sanofi in a report on Monday, October 8th. They issued a neutral rating for the company. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of Sanofi in a report on Monday, October 15th. Finally, Barclays raised Sanofi from an underweight rating to an equal weight rating in a report on Thursday, November 1st. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $51.00.
Sanofi (NYSE:SNY) last posted its quarterly earnings results on Thursday, February 7th. The company reported $0.63 EPS for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.01. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm had revenue of $9 billion during the quarter, compared to analyst estimates of $9 billion. During the same period last year, the company earned $1.06 earnings per share. The business’s revenue for the quarter was up 3.5% on a year-over-year basis. Analysts anticipate that Sanofi will post 3.1 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of SNY. Essex Savings Bank bought a new stake in Sanofi during the fourth quarter valued at $30,000. Lavaca Capital LLC bought a new stake in Sanofi during the fourth quarter valued at $51,000. Focused Wealth Management Inc boosted its stake in Sanofi by 33.2% during the fourth quarter. Focused Wealth Management Inc now owns 1,204 shares of the company’s stock valued at $52,000 after buying an additional 300 shares during the period. Doyle Wealth Management bought a new stake in Sanofi during the fourth quarter valued at $74,000. Finally, Parallel Advisors LLC boosted its stake in Sanofi by 48.1% during the fourth quarter. Parallel Advisors LLC now owns 1,760 shares of the company’s stock valued at $76,000 after buying an additional 572 shares during the period. 7.04% of the stock is owned by institutional investors.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.